Travere Therapeutics, Inc. (TVTX)
52.33
+0.31
(+0.60%)
USD |
NASDAQ |
Oct 13, 12:42
Travere Therapeutics Cash from Investing (Quarterly) : -206.29M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -206.29M |
| March 31, 2026 | 21.55M |
| December 31, 2025 | -104.84M |
| September 30, 2025 | 86.59M |
| June 30, 2025 | 4.85M |
| March 31, 2025 | 41.29M |
| December 31, 2024 | -80.31M |
| September 30, 2024 | 46.13M |
| June 30, 2024 | 28.61M |
| March 31, 2024 | 104.90M |
| December 31, 2023 | -16.95M |
| September 30, 2023 | 133.32M |
| June 30, 2023 | -23.55M |
| March 31, 2023 | -37.04M |
| December 31, 2022 | -36.70M |
| September 30, 2022 | 10.08M |
| June 30, 2022 | -39.10M |
| March 31, 2022 | 33.16M |
| December 31, 2021 | 7.37M |
| September 30, 2021 | 32.52M |
| June 30, 2021 | -71.81M |
| March 31, 2021 | -105.71M |
| December 31, 2020 | -125.51M |
| September 30, 2020 | -43.17M |
| June 30, 2020 | 67.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 39.55M |
| December 31, 2019 | 1.58M |
| September 30, 2019 | 4.465M |
| June 30, 2019 | 25.23M |
| March 31, 2019 | -11.41M |
| December 31, 2018 | -48.80M |
| September 30, 2018 | -161.54M |
| June 30, 2018 | 27.91M |
| March 31, 2018 | -20.85M |
| December 31, 2017 | -0.103M |
| September 30, 2017 | -2.188M |
| June 30, 2017 | 43.77M |
| March 31, 2017 | 4.125M |
| December 31, 2016 | 30.58M |
| September 30, 2016 | -6.167M |
| June 30, 2016 | -4.292M |
| March 31, 2016 | -9.756M |
| December 31, 2015 | -100.46M |
| September 30, 2015 | 51.12M |
| June 30, 2015 | -1.400M |
| March 31, 2015 | -29.86M |
| December 31, 2014 | 1.970M |
| September 30, 2014 | -2.062M |
| June 30, 2014 | -6.057M |
| March 31, 2014 | -31.11M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| TG Therapeutics, Inc. | 1.03M |
| BioMarin Pharmaceutical, Inc. | -5.102B |
| Vertex Pharmaceuticals, Inc. | -45.80M |
| Viridian Therapeutics, Inc. | -231.16M |
| Krystal Biotech, Inc. | -161.58M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 58.07M |
| Cash from Financing (Quarterly) | 187.52M |
| Free Cash Flow | 15.40M |
| Free Cash Flow Per Share (Quarterly) | 0.3958 |
| Free Cash Flow to Equity (Quarterly) | -252.24M |
| Free Cash Flow to Firm (Quarterly) | 39.12M |
| Free Cash Flow Yield | 0.31% |